First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
![]() |
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix's...
Read more: First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study





